CEO & Chairman
Chief Commercial Officer
VP Sales US
Sales Specialist - North East
Bioproduction Sales Manager
Supporting Viral Vector Therapies from PD to Commercialization
- Current bottlenecks in the Industrial AAV production process
- Improvement of the upstream process is critical for cost effective gene therapy manufacturing
Presented by Roel Gordijn, CCO at Polyplus-transfection
Tuesday, March 8, 2022 at 2:30pm EST
Next-Generation Transfection Reagent for Large Scale AAV Manufacturing
Mathieu Porte, Mégane Denu, Marine Ricordel, Jonathan Havard, Coralie Stritt, Yann Philipson, Malik Hellal, Patrick Erbacher
ATMPs have demonstrated their success with already more than ten approved for commercialization. A major challenge for translation of promising research to clinical development is the manufacture of sufficient quantities of AAV. While transient transfection of suspension cells is the most commonly used production platform, scalability of the process is a bottleneck. Here, we present data on novel transfection reagent that combines flexibility of transient transfection with scalability for manufacturing of AAVs in up to 2000L bioreactors.
Our solutions for both protein and virus production
FectoVIR®-AAV: for Recombinant AAV virus production in suspension cells.
PEIpro® product range for a scalable viral vector production for Gene & Cell therapy.